MiMedx offers an unusually favorable risk-reward setup and a 3-of-4 earnings beat streak, but a sharp revenue decline and a death-cross-confirmed technical downtrend keep the position squarely in speculative, recovery-dependent territory.
Thesis pillars
- Sharp Revenue Decline→Stable
- Favorable Risk Reward↑Improving
- Death Cross Downtrend Recovery↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 5, 2026, based on the 10-K filed Feb 25, 2026· older than 90 days
MiMedx Group, Inc (MDXG) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $3.25: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 5.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend.
MiMedx Group develops and markets placental tissue allografts and, since 2024, animal-derived xenografts for wound care, burn, and surgical applications, manufacturing its PURION-processed products from donated birth tissue at facilities in Marietta and Kennesaw, Georgia. The... Read more
Sell if holding. Engine safety override at $3.25: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 5.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.3/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 112d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
About MiMedx Group, Inc
About MiMedx Group, Inc
MiMedx sells placental tissue allografts under brands including EPIFIX, EPICORD, and AMNIOFIX, plus the bovine-collagen xenograft HELIOGEN launched in 2024, with domestic sales making up the vast majority of the company's revenue. Approximately 43% of 2025 sales came from customers belonging to the company's primary Group Purchasing Organizations and Integrated Delivery Networks, and roughly 26% moved through independent sales agents rather than a direct sales force.
MiMedx generates revenue from Wound Care and Surgical applications, manufacturing allografts through its patented PURION process at two Georgia facilities using donated placental tissue recovered through hospital partnerships, supplemented by exclusive distribution agreements signed in 2025 and early 2026 for products such as RegenKit-Wound Gel, NovaForm Wound Matrix, and Hydrelix Collagen Matrix. Reimbursement dynamics are central to the business: at the end of 2025, CMS announced a shift to a flat $127.14-per-square-centimeter reimbursement rate for skin substitutes across hospital outpatient and physician-office settings beginning January 1, 2026, replacing the prior ASP-plus-6% methodology. Internationally, MiMedx sells EPIFIX through distribution partner Gunze Medical in Japan, where the product holds the only amniotic tissue approval for wound treatment. The company also competes with tissue processors such as Surgenex, against whom MiMedx has pursued patent infringement litigation.
Show full overview
A regulatory dispute over AXIOFILL illustrates classification risk facing tissue processors: after 2023 FDA inspections produced Form 483 observations at both Georgia facilities, the agency issued a December 2023 warning letter and, in March 2024, a Request for Designation determination reaffirming that AXIOFILL does not qualify as a Section 361 human-tissue product. MiMedx has since sued the FDA in the Northern District of Georgia while continuing to market AXIOFILL during the litigation, an outcome that could reclassify the product under stricter drug or biologic pathways if the company's challenge fails.
See also: Healthcare · Biotechnology
From MiMedx Group, Inc's most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated Oct 29, 2026Recent Developments — MiMedx Group, Inc
Latest news
- NEWS MiMedx Group Inc (MDXG) (Q3 2026) Earnings Call Highlights: Revenue Jumps 36% as Neurosurgery ... - Yahoo Finance — Yahoo Finance Oct 29, 2026 positive
- NEWS MiMedx (MDXG) Q3 2026 Earnings Call Transcript - The Globe and Mail — The Globe and Mail Oct 29, 2026 neutral
- NEWS MiMedx (MDXG) Secures $25M Licensing Deal Settling Patent Dispute - GuruFocus — GuruFocus Oct 28, 2026 positive
- NEWS MiMedx enters $25M patent license agreement with wound care competitor - TipRanks — TipRanks Oct 28, 2026 positive
- NEWS MiMedx: Q3 Earnings Snapshot - Yahoo Finance — Yahoo Finance Oct 28, 2026 neutral
Latest item Oct 29, 2026 · Generated 2026-11-04T11:59:36Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Unprofitable operations — net margin -6.3%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $3.25: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 5.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $3.05. Score 5.3/10, moderate confidence.
Analyst target: $6.09 (+87.4% upside). Prior stop was $3.05. Stop-loss: $3.05.
Quality below floor (3.9 < 4.0); Value-trap signals (2/5): Margin compression (op margin -33.3%), Negative free cash flow.
MiMedx Group, Inc trades at a P/E of N/A (forward 30.5). TrendMatrix value score: 8.3/10. Verdict: Sell.
11 analysts rate MDXG, with a consensus score of 4.1/5. 5 analysts publish price targets averaging $7.
What does MiMedx Group, Inc do?MiMedx Group develops and markets placental tissue allografts and, since 2024, animal-derived xenografts for wound...
MiMedx Group develops and markets placental tissue allografts and, since 2024, animal-derived xenografts for wound care, burn, and surgical applications, manufacturing its PURION-processed products from donated birth tissue at facilities in Marietta and Kennesaw, Georgia. The company sells primarily to U.S. hospitals, wound care clinics and physician offices through a direct sales force, independent sales agents, and distributors, with domestic sales making up the vast majority of revenue and international expansion focused on Japan through distribution partner Gunze Medical.